ESCAPE is developing first-in-class therapies that are precisely targeted towards genetically validated targets and pathways that are perturbed in genetic forms of neurodegenerative diseases. Precisely targeting known genetic mechanisms and deploying our compounds in genetically defined patient populations is expected to improve patient outcomes in diseases while avoiding the liabilities of non-selective approaches.
